斑蝥酸钠维生素B6注射液与化疗药物联合治疗非小细胞肺癌的效果分析  

Analysis of the Effectiveness of Combined Treatment of Non-small Cell Lung Cancer with Sodium Cantharidinate/Vitamin B6 Injection and Chemotherapeutic Drugs

作　　者：颜海强 YAN Haiqiang(Department of Thoracic Cardiothoracic Surgery,Ningde Hospital Affiliated to Ningde Normal University,Ningde,Fujian Province,352000 China)

机构地区：[1]宁德师范学院附属宁德市医院胸心外科,福建宁德352000

出　　处：《世界复合医学》2023年第11期16-19,共4页World Journal of Complex Medicine

摘　　要：目的分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者在化疗药物的基础上联合斑蝥酸钠维生素B6注射液(sodium cantharidinate/vitamin B6,SC/VB6)治疗取得的效果。方法方便选取2022年6月—2023年5月宁德师范学院附属宁德市医院收治的88例NSCLC患者为研究对象,按照随机数表法分为对照组和研究组,每组44例。对照组采用常规化疗治疗,研究组采用SC/VB6注射液与化疗联合治疗。比较两组患者治疗疗效,肿瘤标志物水平,以及不良反应发生率。结果研究组治疗有效率54.55%高于对照组,差异有统计学意义(χ^(2)=4.632,P<0.05)。治疗后,研究组细胞角蛋白19片段、神经元特异性烯醇化酶、癌胚抗原低于对照组,差异有统计学意义(P<0.05)。研究组胃肠道反应及骨髓抑制的发生率显著低于对照组,差异有统计学意义(P<0.05),两组患者肝肾功能异常、周围神经毒性发生率比较,差异无统计学意义(P>0.05)。结论化疗联合SC/VB6注射液治疗可改善NSCLC患者肿瘤标志物水平,保障治疗效果,降低不良反应发生率。Objective To analyze the effect of sodium cantharidinate/vitamin B6 injection(SC/VB6)combined with chemotherapeutic drugs in the treatment of non-small cell lung cancer(NSCLC)patients.Methods A total of 88 patients with NSCLC admitted to Ningde Hospital Affiliated to Ningde Normal University from June 2022 to May 2023 were conveniently selected as the study objects,and were divided into control group and study group according to random number table method,with 44 patients in each group.The control group was treated with conventional chemotherapy,and the study group was treated with SC/VB6 injection combined with chemotherapy.The therapeutic efficacy,tumor marker levels,and incidence of adverse reactions were compared between the two groups.Results The effective rate of the study group 54.55%was higher than that of the control group,the difference was statistically significant(χ^(2)=4.632,P<0.05).After treatment,cytokeratin 19 fragment,neuron-specific enolase,and carcinoembryonic antigen in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of gastrointestinal reactions and myelosuppression in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05),and there was no significant difference in the incidence of abnormalities of liver and renal function and peripheral neurotoxicity between the two groups(P>0.05).Conclusion NSCLC patients treated with SC/VB6 injection in combination with chemotherapy can improve the level of tumor markers,safeguard the therapeutic effect and reduce the adverse reactions.

关 键 词：化疗药物 斑蝥酸钠维生素B6注射液 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]